IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC.
暂无分享,去创建一个
N. Reinmuth | T. Mekhail | A. Morabito | A. Sadiq | A. Sandler | M. Kowanetz | H. West | D. Daniel | M. Hussein | M. Mccleod | S. McCune | H. Kopp | A. Rittmeyer | A. Zer | V. Archer | H. Conter | F. Cappuzzo | L. Wang | T. Ochi Lohmann | W. Lin